Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
6 studies found for:    plinabulin
Show Display Options
Rank Status Study
1 Recruiting Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
Conditions: ALK Gene Translocation;   EGFR Activating Mutation;   Recurrent Non-Small Cell Lung Carcinoma;   ROS1 Gene Translocation;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Plinabulin
2 Recruiting Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Drug: Nivolumab + Plinabulin
3 Recruiting Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Docetaxel + Plinabulin (DP);   Drug: Docetaxel (D)
4 Recruiting Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy
Condition: Chemotherapy-induced Neutropenia
Interventions: Drug: Plinabulin;   Drug: Pegfilgrastim;   Other: Saline Placebo;   Other: D5W Placebo
5 Completed Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Cancer
Interventions: Drug: docetaxel;   Drug: NPI-2358 + docetaxel
6 Completed Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
Condition: Cancer
Intervention: Drug: NPI-2358

Study has passed its completion date and status has not been verified in more than two years.